Cargando…

Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection

The kinetics and magnitude of antibody responses to different proteins of the SARS-CoV-2 virus in Sinopharm/BBIBP-CorV vaccinees has not been previously studied. Therefore, we investigated antibody responses to different SARS-CoV-2 proteins at 2 weeks, 3 months, and 6 months post-second dose in prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeewandara, Chandima, Aberathna, Inoka Sepali, Dayarathna, Shashika, Nimasha, Thashmi, Ranasinghe, Thushali, Jayamali, Jeewantha, Kamaladasa, Achala, Karunanada, Maneshka, Perera, Lahiru, Ogg, Graham S., Malavige, Gathsaurie Neelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560485/
https://www.ncbi.nlm.nih.gov/pubmed/36227884
http://dx.doi.org/10.1371/journal.pone.0274845
_version_ 1784807757370621952
author Jeewandara, Chandima
Aberathna, Inoka Sepali
Dayarathna, Shashika
Nimasha, Thashmi
Ranasinghe, Thushali
Jayamali, Jeewantha
Kamaladasa, Achala
Karunanada, Maneshka
Perera, Lahiru
Ogg, Graham S.
Malavige, Gathsaurie Neelika
author_facet Jeewandara, Chandima
Aberathna, Inoka Sepali
Dayarathna, Shashika
Nimasha, Thashmi
Ranasinghe, Thushali
Jayamali, Jeewantha
Kamaladasa, Achala
Karunanada, Maneshka
Perera, Lahiru
Ogg, Graham S.
Malavige, Gathsaurie Neelika
author_sort Jeewandara, Chandima
collection PubMed
description The kinetics and magnitude of antibody responses to different proteins of the SARS-CoV-2 virus in Sinopharm/BBIBP-CorV vaccinees has not been previously studied. Therefore, we investigated antibody responses to different SARS-CoV-2 proteins at 2 weeks, 3 months, and 6 months post-second dose in previously infected (n = 20) and uninfected (n = 20) Sinopharm/BBIBP-CorV vaccinees. The IgG antibodies to the S, S1 and S2 and N were several folds higher in those who had natural infection compared to uninfected individuals at all time points. We then compared the persistence of antibody responses and effect of natural omicron infection or BNT162b2 booster in Sinopharm/BBIBP-CorV vaccinees. We measured the total antibodies to the RBD, ACE2 blocking antibodies and antibody responses to different SARS-CoV-2 proteins in Sinopharm vaccinees at 7 months post second dose, including those who remained uninfected and not boosted (n = 21), or those who had previous infection and who did not obtain the booster (n = 17), those who were not infected, but who received a BNT162b2 booster (n = 30), or those who did not receive the booster but were infected with omicron (n = 29). At 7 months post second dose uninfected (no booster) had the lowest antibody levels to the RBD, while omicron infected vaccinees showed significantly higher anti-RBD antibody levels (p = 0.04) than vaccinees who received the booster. Only 3/21 cohort A (14.3%) had ACE2 blocking antibodies, while higher frequencies were observed in naturally infected individuals (100%), those who received the booster (18/21, 85.7%), and omicron infected individuals (100%). Pre-vaccination, naturally infected had the highest antibody levels to the N protein. These data suggest that those previously infected Sinopharm/BBIBP-CorV vaccinees have a robust antibody response, 7 months post vaccination, while vaccinees who were naturally infected with omicron had a similar immune response to those who received the booster. It will be important to investigate implications for subsequent clinical protection.
format Online
Article
Text
id pubmed-9560485
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95604852022-10-14 Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection Jeewandara, Chandima Aberathna, Inoka Sepali Dayarathna, Shashika Nimasha, Thashmi Ranasinghe, Thushali Jayamali, Jeewantha Kamaladasa, Achala Karunanada, Maneshka Perera, Lahiru Ogg, Graham S. Malavige, Gathsaurie Neelika PLoS One Research Article The kinetics and magnitude of antibody responses to different proteins of the SARS-CoV-2 virus in Sinopharm/BBIBP-CorV vaccinees has not been previously studied. Therefore, we investigated antibody responses to different SARS-CoV-2 proteins at 2 weeks, 3 months, and 6 months post-second dose in previously infected (n = 20) and uninfected (n = 20) Sinopharm/BBIBP-CorV vaccinees. The IgG antibodies to the S, S1 and S2 and N were several folds higher in those who had natural infection compared to uninfected individuals at all time points. We then compared the persistence of antibody responses and effect of natural omicron infection or BNT162b2 booster in Sinopharm/BBIBP-CorV vaccinees. We measured the total antibodies to the RBD, ACE2 blocking antibodies and antibody responses to different SARS-CoV-2 proteins in Sinopharm vaccinees at 7 months post second dose, including those who remained uninfected and not boosted (n = 21), or those who had previous infection and who did not obtain the booster (n = 17), those who were not infected, but who received a BNT162b2 booster (n = 30), or those who did not receive the booster but were infected with omicron (n = 29). At 7 months post second dose uninfected (no booster) had the lowest antibody levels to the RBD, while omicron infected vaccinees showed significantly higher anti-RBD antibody levels (p = 0.04) than vaccinees who received the booster. Only 3/21 cohort A (14.3%) had ACE2 blocking antibodies, while higher frequencies were observed in naturally infected individuals (100%), those who received the booster (18/21, 85.7%), and omicron infected individuals (100%). Pre-vaccination, naturally infected had the highest antibody levels to the N protein. These data suggest that those previously infected Sinopharm/BBIBP-CorV vaccinees have a robust antibody response, 7 months post vaccination, while vaccinees who were naturally infected with omicron had a similar immune response to those who received the booster. It will be important to investigate implications for subsequent clinical protection. Public Library of Science 2022-10-13 /pmc/articles/PMC9560485/ /pubmed/36227884 http://dx.doi.org/10.1371/journal.pone.0274845 Text en © 2022 Jeewandara et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jeewandara, Chandima
Aberathna, Inoka Sepali
Dayarathna, Shashika
Nimasha, Thashmi
Ranasinghe, Thushali
Jayamali, Jeewantha
Kamaladasa, Achala
Karunanada, Maneshka
Perera, Lahiru
Ogg, Graham S.
Malavige, Gathsaurie Neelika
Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title_full Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title_fullStr Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title_full_unstemmed Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title_short Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
title_sort comparison of the kinetics and magnitude of antibody responses to different sars-cov-2 proteins in sinopharm/bbibp-corv vaccinees following the bnt162b2 booster or natural infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560485/
https://www.ncbi.nlm.nih.gov/pubmed/36227884
http://dx.doi.org/10.1371/journal.pone.0274845
work_keys_str_mv AT jeewandarachandima comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT aberathnainokasepali comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT dayarathnashashika comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT nimashathashmi comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT ranasinghethushali comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT jayamalijeewantha comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT kamaladasaachala comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT karunanadamaneshka comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT pereralahiru comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT ogggrahams comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection
AT malavigegathsaurieneelika comparisonofthekineticsandmagnitudeofantibodyresponsestodifferentsarscov2proteinsinsinopharmbbibpcorvvaccineesfollowingthebnt162b2boosterornaturalinfection